Literature DB >> 2974034

Proteolytic processing of mullerian inhibiting substance produces a transforming growth factor-beta-like fragment.

R B Pepinsky1, L K Sinclair, E P Chow, R J Mattaliano, T F Manganaro, P K Donahoe, R L Cate.   

Abstract

Mullerian inhibiting substance (MIS) is a differentiation factor that causes the Mullerian duct to regress during the development of the male reproductive tract. The active form is a disulfide-linked dimer consisting of two identical 70-kDa subunits. Recently, the amino acid sequence for MIS was deduced from its gene sequence and revealed that the carboxyl-terminal region shares homology with transforming growth factor (TGF)-beta. Since TGF-beta is produced as a large latent precursor that requires proteolytic activation for activity, we sought to determine if MIS might undergo a similar processing event. Here we demonstrate that typically 5 to 20% of the protein in MIS preparations is cleaved at a site 109 amino acids from the carboxyl terminus. Concurrent cleavages from both chains of the MIS dimer produces a 25-kDa TGF-beta-like fragment and a high molecular mass complex derived from the amino terminus of the protein. Although the two fragments are noncovalently linked, they remain tightly associated after cleavage, and thus are structurally organized like TGF-beta within its precursor. The same cleavage products also can be generated by limited proteolysis with plasmin, which provides a simple method for converting the entire preparation into the cleaved form. The plasmin-digested MIS is fully active in the organ culture assay.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2974034

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  35 in total

Review 1.  Embryology and classification of intersex states.

Authors:  N Josso
Journal:  Indian J Pediatr       Date:  1992 Jul-Aug       Impact factor: 1.967

2.  Transforming growth factor-ßs as modulators of pericellular proteolytic events.

Authors:  J Keski-Oja; J Lohi; M Laiho
Journal:  Cytotechnology       Date:  1989-12       Impact factor: 2.058

3.  Identification of transforming growth factor beta family members present in bone-inductive protein purified from bovine bone.

Authors:  A J Celeste; J A Iannazzi; R C Taylor; R M Hewick; V Rosen; E A Wang; J M Wozney
Journal:  Proc Natl Acad Sci U S A       Date:  1990-12       Impact factor: 11.205

4.  Processing of anti-mullerian hormone regulates receptor activation by a mechanism distinct from TGF-beta.

Authors:  Nathalie di Clemente; Soazik P Jamin; Alexey Lugovskoy; Paul Carmillo; Christian Ehrenfels; Jean-Yves Picard; Adrian Whitty; Nathalie Josso; R Blake Pepinsky; Richard L Cate
Journal:  Mol Endocrinol       Date:  2010-09-22

5.  Plasminogen Deficiency Delays the Onset and Protects from Demyelination and Paralysis in Autoimmune Neuroinflammatory Disease.

Authors:  Maureen A Shaw; Zhen Gao; Kathryn E McElhinney; Sherry Thornton; Matthew J Flick; Adam Lane; Jay L Degen; Jae Kyu Ryu; Katerina Akassoglou; Eric S Mullins
Journal:  J Neurosci       Date:  2017-03-08       Impact factor: 6.167

Review 6.  Emerging Roles of Anti-Müllerian Hormone in Hypothalamic-Pituitary Function.

Authors:  Anne-Laure Barbotin; Maëliss Peigné; Samuel Andrew Malone; Paolo Giacobini
Journal:  Neuroendocrinology       Date:  2019-07-05       Impact factor: 4.914

Review 7.  Müllerian inhibiting substance/anti-Müllerian hormone: a potential therapeutic agent for human ovarian and other cancers.

Authors:  David T MacLaughlin; Patricia K Donahoe
Journal:  Future Oncol       Date:  2010-03       Impact factor: 3.404

8.  Development of an efficiently cleaved, bioactive, highly pure FLAG-tagged recombinant human Mullerian Inhibiting Substance.

Authors:  Thanos D Papakostas; Rafael Pieretti-Vanmarcke; Fotini Nicolaou; Aristomenis Thanos; George Trichonas; Xanthi Koufomichali; Kosisochukwu Anago; Patricia K Donahoe; Jose Teixeira; David T MacLaughlin; Demetrios Vavvas
Journal:  Protein Expr Purif       Date:  2009-09-13       Impact factor: 1.650

9.  An albumin leader sequence coupled with a cleavage site modification enhances the yield of recombinant C-terminal Mullerian Inhibiting Substance.

Authors:  D Pépin; M Hoang; F Nicolaou; K Hendren; L A Benedict; A Al-Moujahed; A Sosulski; A Marmalidou; D Vavvas; P K Donahoe
Journal:  Technology       Date:  2013-09

10.  Impact of female age and male infertility on ovarian reserve markers to predict outcome of assisted reproduction technology cycles.

Authors:  Tsung-Hsien Lee; Chung-Hsien Liu; Chun-Chia Huang; Kung-Chen Hsieh; Pi-Mei Lin; Maw-Sheng Lee
Journal:  Reprod Biol Endocrinol       Date:  2009-09-17       Impact factor: 5.211

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.